NATALIA LAPTEVA to Cancer Vaccines
This is a "connection" page, showing publications NATALIA LAPTEVA has written about Cancer Vaccines.
Connection Strength
0.859
-
CCL5 as an adjuvant for cancer immunotherapy. Expert Opin Biol Ther. 2010 May; 10(5):725-33.
Score: 0.304
-
Targeting the intratumoral dendritic cells by the oncolytic adenoviral vaccine expressing RANTES elicits potent antitumor immunity. J Immunother. 2009 Feb-Mar; 32(2):145-56.
Score: 0.279
-
A composite MyD88/CD40 switch synergistically activates mouse and human dendritic cells for enhanced antitumor efficacy. J Clin Invest. 2011 Apr; 121(4):1524-34.
Score: 0.081
-
Attraction and activation of dendritic cells at the site of tumor elicits potent antitumor immunity. Mol Ther. 2009 Sep; 17(9):1626-36.
Score: 0.072
-
Enhanced activation of human dendritic cells by inducible CD40 and Toll-like receptor-4 ligation. Cancer Res. 2007 Nov 01; 67(21):10528-37.
Score: 0.064
-
An essential role for Akt1 in dendritic cell function and tumor immunotherapy. Nat Biotechnol. 2006 Dec; 24(12):1581-90.
Score: 0.060